Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1
Importance Therapies to inhibit programmed cell death 1 and its ligand (anti–PD-1/PD-L1)
provide significant survival benefits in many cancers, but the efficacy of these treatments
varies considerably across different cancer types. Identifying the underlying variables
associated with this cancer type–specific response remains an important open research
challenge. Objective To evaluate systematically a multitude of neoantigen-, checkpoint-, and
immune response–related variables to determine the key variables that accurately predict …
provide significant survival benefits in many cancers, but the efficacy of these treatments
varies considerably across different cancer types. Identifying the underlying variables
associated with this cancer type–specific response remains an important open research
challenge. Objective To evaluate systematically a multitude of neoantigen-, checkpoint-, and
immune response–related variables to determine the key variables that accurately predict …